We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Product News   Apr 15, 2019

 
QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Image credit: QIAGEN

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Phico Therapeutics Raises £7 million Investment

Product News

Phico Therapeutics Ltd has announced £7 million in new investment. The financing was led by the UK’s most active growth capital investor, BGF which invested £3 million and was joined by other existing Phico investors.

READ MORE

Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research

Product News

Flow Eighteen38 and FairJourney Biologics S.A. have announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools.

READ MORE

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2(R)

Product News

Orgenesis Inc. announces it has been granted Investigational Device Exemption (IDE) approval by the United States Food and Drug Administration (FDA) to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2(R) to treat Acute Respiratory Distress Syndrome (ARDS) resulting from COVID-19 infection.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE